About: Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform
Creator	Baric, Ralph Schäfer, Alexandra Agnihothram, Sudhakar Whitmore, Alan Yount, Boyd Scobey, Trevor Heise, Mark Menachery, Vineet Lindesmith, Lisa
Source	Medline; PMC
abstract	Zoonotic viruses circulate as swarms in animal reservoirs and can emerge into human populations, causing epidemics that adversely affect public health. Portable, safe, and effective vaccine platforms are needed in the context of these outbreak and emergence situations. In this work, we report the generation and characterization of an alphavirus replicon vaccine platform based on a non-select agent, attenuated Venezuelan equine encephalitis (VEE) virus vaccine, strain 3526 (VRP 3526). Using both noroviruses and coronaviruses as model systems, we demonstrate the utility of the VRP 3526 platform in the generation of recombinant proteins, production of virus-like particles, and in vivo efficacy as a vaccine against emergent viruses. Importantly, packaging under biosafety level 2 (BSL2) conditions distinguishes VRP 3526 from previously reported alphavirus platforms and makes this approach accessible to the majority of laboratories around the world. In addition, improved outcomes in the vulnerable aged models as well as against heterologous challenge suggest improved efficacy compared to that of previously attenuated VRP approaches. Taking these results together, the VRP 3526 platform represents a safe and highly portable system that can be rapidly deployed under BSL2 conditions for generation of candidate vaccines against emerging microbial pathogens. IMPORTANCE While VEE virus replicon particles provide a robust, established platform for antigen expression and vaccination, its utility has been limited by the requirement for high-containment-level facilities for production and packaging. In this work, we utilize an attenuated vaccine strain capable of use at lower biocontainment level but retaining the capacity of the wild-type replicon particle. Importantly, the new replicon platform provides equal protection for aged mice and following heterologous challenge, which distinguishes it from other attenuated replicon platforms. Together, the new system represents a highly portable, safe system for use in the context of disease emergence.
has issue date	2018-05-14(xsd:dateTime)
bibo:doi	10.1128/jvi.00027-18
bibo:pmid	29540599
has license	cc-by
sha1sum (hex)	e142106dccc14c30910e705e1159d340c6a97832
schema:url	https://doi.org/10.1128/jvi.00027-18
resource representing a document's title	Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform
has PubMed Central identifier	PMC5952155
has PubMed identifier	29540599
schema:publication	J Virol
resource representing a document's body	covid:e142106dccc14c30910e705e1159d340c6a97832#body_text
is schema:about of	named entity 'VACCINE' named entity 'provide' named entity 'platform' named entity 'heterologous' named entity 'Accessible' named entity 'DEVELOPMENT' named entity 'ACCESSIBLE' named entity 'REPORTED' named entity 'SELECT' named entity 'CANDIDATE' named entity 'REPORT' named entity 'LEVEL' named entity 'VEE' named entity 'RESERVOIRS' named entity 'EXPRESSION' named entity 'ATTENUATED' named entity 'NON-' named entity 'VENEZUELAN EQUINE ENCEPHALITIS' named entity 'AGED' named entity 'ATTENUATED VACCINE' named entity 'OUTCOMES' named entity 'HIGH' named entity 'VIRUS VACCINE' named entity 'PARTICLE' named entity 'RAPIDLY' named entity 'MODELS' named entity 'ESTABLISHED' named entity 'SUGGEST' named entity 'USE' named entity 'UTILITY' named entity 'ANIMAL' named entity 'PROTECTION' named entity 'USING' named entity 'VACCINE' named entity 'PARTICLES' named entity 'PRODUCTION' named entity 'MAJORITY' named entity 'REPLICON' named entity 'HIGHLY' named entity 'RETAINING' named entity 'ROBUST' named entity 'THESE' named entity 'PLATFORM' named entity 'VULNERABLE' named entity 'EFFICACY' named entity 'AFFECT' named entity 'WORLD' named entity 'VACCINE STRAIN' named entity 'STRAIN' named entity 'FACILITIES' named entity 'IN VIVO' named entity 'VACCINATION' named entity 'CORONAVIRUSES' named entity 'SYSTEM' named entity 'CONTAINMENT' named entity 'PACKAGING' named entity 'CAPABLE' named entity 'PROVIDE' named entity 'EMERGE' named entity 'SYSTEMS' named entity 'VRP' named entity 'LOWER' named entity 'REQUIREMENT' named entity 'APPROACHES' named entity 'AGENT' named entity 'EPIDEMICS' named entity 'CAPACITY' named entity 'COMPARED' named entity 'MICROBIAL PATHOGENS' named entity 'VENEZUELAN EQUINE ENCEPHALITIS VIRUS' named entity 'ACCESSIBLE' named entity 'ITS' named entity 'PLATFORM'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software